348150 — KoBioLabs Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesHighly SpeculativeSmall CapSucker Stock

Annual income statement for KoBioLabs, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	4,591	2,893	11,606	33,138	68,359
Cost of Revenue
Gross Profit	2,642	1,909	8,021	23,731	46,816
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	16,928	19,238	31,892	51,576	74,803
Operating Profit	-12,336	-16,344	-20,286	-18,438	-6,444
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-55,072	-16,368	-23,030	-14,683	-4,178
Provision for Income Taxes
Net Income After Taxes	-55,072	-15,382	-23,386	-15,158	-4,617
Minority Interest
Net Income Before Extraordinary Items
Net Income	-55,072	-15,382	-21,921	-13,853	-5,298
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-55,072	-15,382	-21,921	-13,853	-5,298
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-3,549	-945	-1,305	-748	-288
Dividends per Share